IBD: Incidence of HSV and HPV with azathioprine

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 8, 2009, Pages 444-445

  Cottone, Mario ^a   Renna, Sara ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; WART VIRUS VACCINE;

AGE; ANAMNESIS; ARTICLE; CANCER SCREENING; CANDIDIASIS; CASE CONTROL STUDY; CLINICAL FEATURE; CROHN DISEASE; DISEASE EXACERBATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ENTERITIS; GYNECOLOGICAL EXAMINATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INNATE IMMUNITY; NUTRITIONAL STATUS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SURGICAL PATIENT; ULCERATIVE COLITIS; VACCINATION; VARICELLA ZOSTER VIRUS; VERRUCA VULGARIS; WART VIRUS;

AZATHIOPRINE; HERPES SIMPLEX; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; OPPORTUNISTIC INFECTIONS; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS;

EID: 68449104740     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.110     Document Type: Article

References (10)

1. Toruner, M. et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 929-936 (2008).
2. Lichtenstein, G. R. et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4, 621-630 (2006).
3. Beaugerie, L. et al. The use of immunomodulators and biologics in inflammatory bowel diseases (IBD): A cross-sectional French nationwide cohort 2004-2005 [Abstract]. Gastroenterology 130 (4 Suppl. 2 A2 (2006).
4. Kane, S., Khatibi, B. & Reddy, D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am. J. Gastroenterol. 103, 631-636 (2008).
5. Korelitz, B. I., Fuller, S. R., Warman, J. I. & Goldberg, M. D. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am. J. Gastroenterol. 94, 424-426 (1999).
6. Gupta, G., Lautenbach, E. & Lewis, J. D. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4, 1483-1490 (2006).
7. Seksik, P. et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment. Pharmacol. Ther. 29, 1106-1113 (2009).
8. Spencer, E. S. & Andersen, H. K. Viral infections in renal allograft recipients treated with long-term immunosuppression. Br. Med. J. 2, 829-830 (1979).
9. Warman, J. I., Korelitz, B. I., Fleisher, M. R. & Janardhanam, R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J. Clin. Gastroenterol. 37, 220-225 (2003).
10. Viget, N., Vernier-Massouille, G., Salmon-Ceron, D., Yazdanpanah, Y. & Colombel, J. F. Opportunistic infections in patients with inflammatory bowel disease: Prevention and diagnosis. Gut 57, 549-558 (2008).